In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Curing What Ails Alzheimer’s Drug Development

Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

BioPharmaceutical Business Strategies Innovation

Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio

Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.

BioPharmaceutical Growth Business Strategies

Market Access: Japan Is Not An Add-On For Medtech Manufacturers

Too risky? Too costly? Global medtech innovators have tended to look at Japan as a market they might graduate to after cracking the US and EU. But Japan has changed in recent years and offers opportunities to medtech companies with products for unmet needs, as long as those firms are willing to commit themselves to understanding the dynamics of the market and its unique aspects.

Market Access Japan Medical Device

In Vivo Needs Your Feedback!

Please take our brief reader survey to help In Vivo evolve to meet your needs in 2018. No strings attached, and those who complete the survey will be in the running for Amazon gift vouchers.

BioPharmaceutical Medical Device
Advertisement

Human Capital
In The Life Sciences

Insights from In Vivo & EBD Academy's survey of senior executives


Recent Tweets from In Vivo


Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap

Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.

BioPharmaceutical Research and Development Strategies

True To Its Word, LivaNova Sheds CRM – To MicroPort

One of the cleanest and swiftest M&A deals of recent months was the twinning of LivaNova's CRM business with MicroPort's enhanced ambitions in a $10 billion global market. What now for these two medtech innovators?

Business Strategies M & A

LivaNova Builds Strategic Base And Commercial Case To Silence Skeptics

Medical innovator LivaNova has a new stated focus: it won’t go outside the head and the heart when it comes to potential M&A and technology development projects. It has set out short- and longer-term solutions to boost sales and/or profitability in its neuromodulation and cardio franchises. What is certain is that eight months into his tenure as CEO, Damien McDonald is stamping his imprint all over LivaNova.

Growth Business Strategies

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

TxCell: Regen Med Firm's CEO Starts From Scratch

Since becoming CEO of TxCell two years ago, Stéphane Boissel has reorganized the R&D plan, restructured and reduced the head count and put the company on the road to scalable manufacturing of CAR-T regulatory cells. And he has put strategic partnerships on the agenda. It is a big change from the situation 12 months ago, he told In Vivo during the Annual European Advanced Therapies Investor Day.

Business Strategies Regenerative Medicine

GSK Woes Raise Big Pharma R&D Question

GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.

BioPharmaceutical Business Strategies

CAR-T Commercialization Strategies: Views From Novartis And Kite

At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.

Regenerative Medicine Commercial

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, January 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Execs On The Move, December 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Pfizer’s Safe House: Peter Honig Builds A Regulatory Model For The Future

In Vivo talks to Pfizer SVP for worldwide safety and regulatory Peter Honig on the challenges of establishing – and then maintaining – the confidence of a diverse array of constituencies in the safe, effective use of medicines for a $50 billion business.   

BioPharmaceutical Safety

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

What Will Keep Medtech Industry Leaders Awake At Night In 2018?

Brian Chapman, principal at ZS consultancy, spends a lot of time predicting, analyzing and solving market access hurdles and opportunities for clients within the group's medical products and services division. Here he tells In Vivo what is preoccupying the thoughts of the industry's leaders as 2018 gets underway, and suggests two key areas where he thinks change would reap dividends for all stakeholders.

International Market Access

Tracking Transparency In Clinical Trials: Progress But To What Standard?

A second survey by the independent NGO Bioethics International shows significant improvement in big pharma’s willingness to share data on clinical trials for important novel drugs. Expectations for further progress remain high, but consensus around a globally consistent, measurable standard is still a long slog.

Clinical Trials BioPharmaceutical

Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

On October 5, In Vivo convened a group of top market-access specialists and industry and investment analysts to consider a central strategic challenge facing all innovators in biopharma: how to pay for the next wave of cures. Finding the answer first depends on a rebranding of the function itself – it’s not market access to products; it’s patient access to progress.

BioPharmaceutical Market Access

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

In Vivo's 2017 Deals Of The Year: The Winners Are…

We nominated 15 deals in three categories. You picked the winners.

Deals Market Intelligence

2017's Top Biopharma Deal-makers

A co-development and co-commercialization agreement between AstraZeneca and Merck, one of the largest of 2017, continued the dominance of immuno-oncology in partnerships. There was significant consolidation in the consumer health industry, coupled with CVS and Aetna's major move to change health care delivery.

Deals Market Intelligence

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical
UsernamePublicRestriction

Register

Advertisement